FDA acceptance de-risks the BLA review process and sets a clear catalyst date. Traders should watch for any FDA advisory committee announcement or briefing documents ahead of the PDUFA date. The strong Phase 3 data supports approval probability, but binary risk remains until April 14, 2027.
Price Chart
Executive Summary
Inhibrx announced FDA acceptance of its BLA for ozekibart (INBRX-109) in unresectable or metastatic conventional chondrosarcoma, with no filing review issues and a PDUFA goal date of April 14, 2027. The BLA is supported by positive Phase 3 ChonDRAgon data showing a 52% reduction in risk of progression or death (HR 0.479, p<0.0001) and a doubling of median PFS. This is a major regulatory milestone for a first-in-class therapy in a disease with no approved systemic options.
Key Facts
- FDA accepted BLA for ozekibart (INBRX-109) for unresectable or metastatic conventional chondrosarcoma
- No filing review issues identified by FDA
- PDUFA goal date set for April 14, 2027
- Phase 3 ChonDRAgon study met primary endpoint: 52% reduction in risk of progression or death (HR 0.479, 95% CI 0.33-0.68, p<0.0001)
- Median PFS 5.52 months vs 2.66 months for placebo
- Ozekibart would be first FDA-approved systemic therapy for this indication if approved
- Company is clinical-stage with no approved products; ozekibart would be first commercial product
Financial Impact
No financial figures provided in filing; potential for first commercial revenue if approved, but no revenue currently
Risk Factors
- FDA may issue a Complete Response Letter or require additional data
- Potential safety concerns (hepatotoxicity) could delay or prevent approval
- Commercial launch execution risk if approved
- Competition from other therapies in development for chondrosarcoma
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0002007919-26-000033 |
| Exhibit: exhibit991-pressreleasebla.htm | 0002007919-26-000033 |
| Document: 0002007919-26-000033-index-headers.html | 0002007919-26-000033 |
| Document: 0002007919-26-000033-index.html | 0002007919-26-000033 |
| Document: 0002007919-26-000033.txt | 0002007919-26-000033 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 14, 2026 12d ago | Insider Buy | $90.50 | awaiting T+60 | — | $95.84 (+5.90%) |
Sep 28, 2026 28d ago | Insider Cluster | $104.83 | awaiting T+60 | — | $95.84 (−8.58%) |
Sep 17, 2026 5w ago | Insider Cluster | $109.35 | awaiting T+60 | — | $95.84 (−12.35%) |
Sep 15, 2026 5w ago | Insider Cluster | $101.77 | awaiting T+60 | — | $95.84 (−5.83%) |
Sep 15, 2026 5w ago | 144 | $101.77 | awaiting T+60 | — | $95.84 (−5.83%) |
Sep 14, 2026 6w ago | 144 | $105.61 | awaiting T+60 | — | $95.84 (−9.25%) |
Sep 11, 2026 6w ago | 144 | $109.27 | awaiting T+60 | — | $95.84 (−12.29%) |
Sep 10, 2026 6w ago | Insider Cluster | $109.27 | awaiting T+60 | — | $95.84 (−12.29%) |
Sep 8, 2026 6w ago | Insider Cluster | $112.86 | awaiting T+60 | — | $95.84 (−15.08%) |
Sep 8, 2026 6w ago | Insider Buy | $112.86 | awaiting T+60 | — | $95.84 (−15.08%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers